AG Magazine • Health & Nutrition
Your £400-a-month supplement stack may be working. The uncomfortable part is that the biological mechanism driving those results might not be the one printed on the label.
The supplement industry generated over $177 billion globally in 2023 and is projected to exceed $300 billion by 2030. A significant portion of that spend is concentrated in the biohacking and longevity segment — adaptogens, NAD+ precursors, nootropics, peptide stacks — marketed through influencer channels with implied efficacy that often outpaces the clinical evidence behind the product. The supplement stack placebo is not a fringe problem. It is a systematic feature of an industry that monetises optimism.
This is not an argument against supplementation. Several supplements have robust clinical evidence. The argument is for a more precise understanding of what is actually producing the results you are experiencing — because that precision determines whether you spend your money and attention on the variables that genuinely move the needle for you specifically.
The science of placebo, expectation effects, and supplement efficacy is more nuanced — and more interesting — than either the influencer narrative or the reflexive dismissal suggests.
The Placebo Effect Is Not ‘Just in Your Head’
The dismissive phrase ‘it’s just placebo’ fundamentally misrepresents the neuroscience. Placebo responses are not imaginary. They involve measurable changes in neurochemistry, immune function, hormonal output, and physiological performance — produced by expectation, conditioning, and the ritual of taking an intervention.
A landmark 2001 study published in Science demonstrated that placebo administration in Parkinson’s patients triggered genuine dopamine release in the brain — not imagined dopamine, but measured neurochemical activity. The mechanism was expectation alone, without any active drug. Subsequent research has shown that placebo analgesia involves endogenous opioid release, placebo antidepressants produce measurable serotonergic shifts, and placebo performance enhancers generate real increases in exercise output in controlled trials.
The Harvard Program in Placebo Studies — the world’s primary academic centre for this research — has documented what it calls the ‘open-label placebo’ effect: people who are explicitly told they are taking a placebo still show significant physiological improvements in irritable bowel syndrome, chronic pain, and fatigue. The effect is not contingent on deception. It is driven by the ritual, the expectation of care, and the conditioned associations the brain brings to any pill-taking behaviour.
What This Means for Your Supplement Stack
When you take a supplement and notice improved energy, focus, or recovery, several things may be simultaneously true: the active compound is producing a direct physiological effect, the act of taking the supplement is activating expectation-driven neurochemical responses, and the lifestyle behaviours you’ve adopted alongside the supplementation — better sleep, more water, more structured training — are producing independent improvements that get attributed to the pill.
Disentangling these contributions is genuinely difficult, which is why double-blind, placebo-controlled trials exist. The problem is that most of the supplements on your shelf have not been through them — and the influencer presenting them to you has every financial incentive to credit the compound rather than the expectation.
The Evidence Gap: What’s in Your Stack and What the Research Actually Shows
The supplement industry operates under a regulatory framework that does not require pre-market efficacy evidence. In the United States, the Dietary Supplement Health and Education Act (DSHEA) of 1994 places the burden of proof on the FDA to demonstrate that a supplement is unsafe — not on the manufacturer to prove it works.
This means that any supplement currently on the market may have been sold for years or decades with no published human efficacy data. The NIH’s National Center for Complementary and Integrative Health (NCCIH) maintains one of the most comprehensive and honestly framed databases of supplement evidence. For many commonly marketed longevity and biohacking supplements — including lion’s mane, ashwagandha at performance doses, and the majority of nootropic blends — the NCCIH notes that evidence is ‘promising but limited’ or ‘based primarily on animal models and small human studies.’ That is a clinical way of saying: we do not yet know if this works in you, at this dose, for this outcome.
The Three-Category Audit
A rigorous supplement audit sorts your current stack into three categories based on evidence depth:
- Category A — Robust human evidence at the dose you’re taking: Creatine monohydrate (Journal of the International Society of Sports Nutrition position stand), vitamin D in deficiency-confirmed individuals (NIH Office of Dietary Supplements), omega-3 fatty acids at 2–4g EPA/DHA for inflammation (American Heart Association).
- Category B — Mechanistically plausible, some human evidence, dose uncertainty: NMN/NR at standard doses (human trials ongoing), ashwagandha for stress biomarkers (Mayo Clinic overview), magnesium glycinate for sleep onset.
- Category C — Animal or in-vitro data extrapolated to human claims, limited or no controlled human trials: The majority of nootropic blends, most adaptogen combinations at the doses in standard products, several ‘longevity’ compounds marketed through biohacking channels.
Most high-spending supplement users have stacks that are 40–60% Category C. That’s not fraud — some Category C compounds may prove efficacious as human trial data matures. But it means a significant portion of your spend is a wager on future science, not a bet on current evidence.
The Nocebo Effect: When Expectation Harms Instead of Helps
If the placebo effect is expectation producing real benefit, the nocebo effect is its mirror: negative expectation producing real harm. In the context of supplement culture, the nocebo problem is underappreciated but consequential.
A 2019 review in the BMJ documented the nocebo effect across multiple clinical trial settings, finding that reported side effects in placebo groups frequently matched the side effect profiles participants had been told to expect — not the pharmacological action of the compound. In one statin trial, patients who knew they were taking statins reported significantly more muscle pain than those given the same drug without detailed side-effect disclosure. The pain was physiologically real; the cause was expectation.
In supplement culture, the nocebo equivalent operates in reverse. Influencers who frame supplement non-use as actively harmful — ‘without this, your mitochondria are degrading right now’ — generate measurable anxiety responses in their audiences that can produce fatigue, brain fog, and reduced perceived energy. This anxiety is then resolved when the supplement is purchased and taken, and the resolution of anxiety is experienced as the supplement ‘working.’ The compound may have done nothing. The anxiety creation and its removal did everything.
The Honest Influencer Problem
This dynamic is not always conscious manipulation. Many influencers genuinely believe in the products they promote, having experienced the placebo-plus-lifestyle-change effect themselves. But the commercial structure of affiliate marketing — where the creator earns on purchase, not outcome — systematically rewards claim amplification. The Federal Trade Commission’s disclosure guidelines require influencers to disclose financial relationships, but they do not regulate the scientific accuracy of supplement claims. The gap between legal compliance and epistemic honesty is where most longevity supplement marketing lives.
⚡ PRO TIP
Run a personal elimination trial before adding any new supplement. Take your current stack, remove one Category B or C compound for 30 days, and track four objective metrics: resting HRV (via wearable), subjective energy (daily 1–10 log), training performance (load × reps), and sleep score. If you cannot detect a measurable difference across these four metrics in 30 days without the supplement, you are paying for expectation, not effect. This is not a reason to feel deceived — expectation has genuine physiological value. But it is information that lets you allocate your supplement budget toward compounds with evidence rather than compounds with momentum. The NIH NCCIH supplement database is free, evidence-graded, and updated regularly — it is the most honest tool available for this audit.
The Supplements With Genuine Evidence: What to Keep
The case against supplement culture’s overclaiming is not a case against supplementation. A subset of compounds has cleared the evidence bar with sufficient rigour to justify consistent use in the target population. The distinguishing feature is not novelty or price — it is the presence of multiple independent, human, double-blind trials with consistent findings.
Compounds With Category A Evidence
Creatine monohydrate remains the single most evidence-backed performance supplement in existence. A 2017 position stand from the International Society of Sports Nutrition reviewed over 500 studies and concluded that creatine supplementation is safe, effective for strength and power output, and — increasingly relevant for longevity contexts — has emerging evidence for neuroprotective and cognitive benefits in older adults. It costs under £10 per month. It outperforms supplements costing 40 times more on an evidence-per-pound basis.
Vitamin D supplementation in individuals with confirmed deficiency reduces all-cause mortality risk and has consistent effects on immune function, musculoskeletal health, and mood. The NIH Office of Dietary Supplements notes that over 40% of U.S. adults are deficient, making this one of the highest-prevalence modifiable risk factors available. The supplement’s value is not in optimisation — it is in correcting a genuine gap that affects a large proportion of the population regardless of how carefully they eat.
Omega-3 fatty acids at therapeutic doses (2–4g EPA/DHA daily) have documented effects on cardiovascular biomarkers, inflammatory markers including C-reactive protein, and triglyceride reduction. The American Heart Association recommends omega-3 supplementation for individuals with elevated cardiovascular risk based on multiple large randomised trials. For the training athlete, the anti-inflammatory mechanism also has plausible recovery benefit — though the performance-specific evidence is less consistent.
The Honest Case for Some Category B Compounds
Magnesium glycinate at 300–400mg before sleep has consistent evidence for sleep onset improvement and anxiety reduction via GABA-receptor modulation, with a safety profile that makes it low-risk at standard doses. The Mayo Clinic’s supplement overview notes that up to 50% of Americans are below the estimated average requirement for magnesium, creating a population-level rationale for supplementation that mirrors the vitamin D argument.
Rebuilding Your Stack on Evidence, Not Momentum
The supplement stack placebo problem is solvable without abandoning supplementation. It requires replacing the influencer-driven addition model — where new compounds get layered on indefinitely — with an evidence-first subtraction model: start from zero, add only compounds with Category A or well-documented Category B evidence, and test each addition individually before stacking.
This reframe is not austerity. It is precision. A stack of three to five evidence-backed compounds, each with a documented mechanism and a personal elimination trial behind it, produces more measurable benefit than a twelve-compound stack where attribution is impossible and budget is diffused across compounds ranging from well-evidenced to speculative.
The Harvard T.H. Chan School of Public Health’s Nutrition Source provides an accessible, evidence-graded overview of vitamins and supplements with honest assessments of what is and is not supported by current research. Cross-referencing your current stack against this resource and the NCCIH database takes less than an hour and will tell you more about the actual evidence profile of your supplementation than any influencer cohort.
What is your supplement stack actually doing? You may find the honest answer is: some compounds are working as claimed, some are working through expectation, and some are doing nothing measurable except generating a comfortable sense of action. Knowing which is which is not a reason for cynicism. It is the foundation for a supplementation strategy that genuinely serves your health rather than your anxiety about it.
Audit the Stack. Keep What Earns Its Place.
The supplement stack placebo is not a scandal. It is a predictable consequence of an industry that monetises optimism and a regulatory framework that does not require proof of efficacy before sale. The placebo effect itself is real, physiologically meaningful, and not worthless — but you deserve to know whether you are paying for pharmacology or expectation.
The motivational reframe is this: the supplements with genuine evidence are, almost uniformly, the least expensive and least glamorous options on the market. Creatine, vitamin D, omega-3, magnesium. None of them have celebrity ambassadors. All of them have hundreds of independent studies. The influencer stack and the evidence stack rarely overlap — and that gap is where your money is going.
This week, run the three-category audit on your current stack. Cross-reference each compound against the NIH NCCIH database and the Harvard Nutrition Source. Remove every Category C compound for 30 days and track your four objective metrics. Your body will tell you what’s actually working. Trust that data more than the testimonial.
